Yin T, Li W, Zhao P, Wang Y, Zheng J
Center of Interventional Oncology and Liver Diseases, Beijing You'an Hospital, Capital Medical University, Beijing 100069, PR China.
Center of Interventional Oncology and Liver Diseases, Beijing You'an Hospital, Capital Medical University, Beijing 100069, PR China.
Clin Radiol. 2017 Feb;72(2):136-140. doi: 10.1016/j.crad.2016.10.022. Epub 2016 Nov 25.
To evaluate the treatment efficacy and potential complications of computed tomography (CT)-guided microwave ablation for primary hepatocellular carcinoma (HCC).
Data were collected and analysed from 220 HCC patients treated with CT-guided microwave ablation and followed up for 2 years. Independent risk factors for overall survival and progression-free survival (PFS) were analysed.
Among all cases followed, the cumulative overall survival rates at 1 and 2 years were 95.45% and 89.09%. The cumulative 1- and 2-year PFS rates were 80.90% and 62.73%. For patients with Barcelona Clinic Liver Cancer (BCLC) class C (n=60), the cumulative 1- and 2-year overall survival rates were 89.09% and 74.54%. In this group, patients with tumour invasion of blood vessels or tumour-related symptoms suffered a worse overall survival compared to those without (p=0.011). No fatal complications were observed. Child-Pugh score (p=0.030) and BCLC class (p=0.012) were independent risk factors for overall survival. The number of tumour nodules was an independent risk factor for reoccurrence.
CT-guided percutaneous microwave ablation could be an effective and safe treatment option for HCC patients.
评估计算机断层扫描（CT）引导下微波消融治疗原发性肝细胞癌（HCC）的疗效及潜在并发症。
收集并分析220例行CT引导下微波消融治疗并随访2年的HCC患者的数据。分析总生存期和无进展生存期（PFS）的独立危险因素。
在所有随访病例中，1年和2年的累积总生存率分别为95.45%和89.09%。1年和2年的累积PFS率分别为80.90%和62.73%。对于巴塞罗那临床肝癌（BCLC）C期患者（n = 60），1年和2年的累积总生存率分别为89.09%和74.54%。在该组中，有血管侵犯或肿瘤相关症状的患者总生存期较无这些情况的患者更差（p = 0.011）。未观察到致命并发症。Child-Pugh评分（p = 0.030）和BCLC分期（p = 0.012）是总生存期的独立危险因素。肿瘤结节数量是复发的独立危险因素。
CT引导下经皮微波消融可为HCC患者提供一种有效且安全的治疗选择。
